



Universiteit
Leiden
The Netherlands

The effect of statin therapy on vessel wall properties in type 2 diabetes without manifest cardiovascular disease

Beishuizen, E.D.

Citation

Beishuizen, E. D. (2008, December 4). *The effect of statin therapy on vessel wall properties in type 2 diabetes without manifest cardiovascular disease*. Retrieved from <https://hdl.handle.net/1887/13309>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/13309>

Note: To cite this publication please use the final published version (if applicable).

Chapter 5

Differential effects of statin therapy on CRP in patients with type 2 diabetes with and without the metabolic syndrome

ED Beishuizen¹, JT. Tamsma¹, JW Jukema²,
MA van de Ree³, JCM van der Vijver⁴, H van Pelt⁵,
MV Huisman¹

¹ Department of General Internal Medicine and Endocrinology, Leiden University Medical Center, Leiden

² Department of Cardiology, Leiden University Medical Center, Leiden

³ Department of Internal Medicine, Diaconessenhuis, Utrecht

⁴ Department of Internal Medicine, HAGA Hospital, The Hague

⁵ Department of Clinical Chemistry, Leiden University Medical Center, Leiden

The Netherlands

submitted

ABSTRACT

Objective

C-reactive protein (CRP) is a marker for the inflammatory process of atherosclerosis. We evaluated the effect of statin therapy on CRP in patients with type 2 diabetes mellitus (DM2) without manifest cardiovascular disease.

Research Design and Methods

A randomized, placebo-controlled double-blind trial was performed in 250 patients with DM2 without manifest cardiovascular disease. Patients were given 0.4 mg cerivastatin or placebo daily. The primary endpoint was the change in high sensitivity CRP after 2 years.

Results

CRP in the statin group was 1.58 mg/L at baseline and 1.69 mg/L at 2 years ($p = 0.413$), in the placebo group it increased from 2.03 mg/L at baseline to 2.54 mg/L at 2 years ($p = 0.058$) ($p = 0.269$ for comparison between the groups). In a high-risk subgroup with the metabolic syndrome and LDL levels > 2.6 mmol/L (40 % of the cohort) CRP levels increased significantly in the placebo group (from 2.97 mg/L at baseline to 3.99 mg/L at 2 years, $p = 0.036$) in comparison to the statin group (from 2.13 mg/L at baseline to 2.10 mg/L at 2 years, $p = 0.885$) ($p = 0.042$ for comparison between the groups)

Conclusions

There was no effect of two year statin therapy on CRP in patients with DM2 without manifest cardiovascular disease, except in a subgroup with the metabolic syndrome and LDL > 2.6 mmol/L. Studies supporting risk stratified therapy in primary prevention in DM2 are needed.

INTRODUCTION

Cardiovascular disease (CVD) is the most important cause of mortality in patients with type 2 diabetes mellitus (DM2)¹. C-reactive protein (CRP) is a marker for the chronic inflammatory process in atherosclerotic plaques, and probably has pro-atherogenic properties of its own²⁻⁴. When measured with high sensitivity assays, CRP levels are highly reproducible, unaffected by food intake and with no circadian variation. CRP is a strong predictor of future cardiovascular events, independent of traditional risk factors such as LDL cholesterol⁵⁻⁷. CRP levels are associated with components of the metabolic syndrome (MS) such as triglycerides, obesity and insulin sensitivity^{8,9}. Finally, CRP might be predictive of incident DM2¹⁰⁻¹².

In DM2 without coronary artery disease, levels of CRP are higher than in non-diabetic controls¹³. CRP levels independently predict future cardiovascular events in DM2 in some studies^{14,15}. Importantly, in the Hoorn study¹⁶, the association of CRP with future CVD events in DM2 was not independent of classical risk factors.

A meta-analysis of intervention studies with statins in the setting of secondary prevention after a cardiovascular event has shown a correlation between reduced cardiovascular events and reduction in CRP, independent of LDL cholesterol lowering¹⁷. Results from intervention studies on the effects of statin therapy on CRP in DM2 have shown contradictory results¹⁸⁻²³. The present study is an analysis of CRP within a randomized, placebo-controlled trial that has evaluated the effect of 2 years' statin therapy on CRP as a pre-specified secondary endpoint in patients with DM2 without CVD.

RESEARCH DESIGN AND METHODS

Subjects and design

The study design and baseline characteristics of the original patient population have been described elsewhere²⁴. Briefly, 250 patients with DM2 for at least one year, aged 30-80 years, without CVD were included between August 1999 and February 2001 in this randomized, double-blind, clinical trial. Patients were given 0.4 mg cerivastatin (Bayer B.V., Mijdrecht, The Netherlands) or placebo daily for 2 years. After the withdrawal of cerivastatin from the market, 0.4 mg cerivastatin was replaced by 20 mg simvastatin (Merck Sharp & Dome, Haarlem, the Netherlands), without unblinding the study. At that moment, all the patients had been randomized with a mean follow-up of 15 months (range 6-23 months).

Eligible patients gave their written informed consent. The study was performed at the Haga Hospital, The Hague. The study was approved by the hospital's Medical Ethics Committee.

Study Objectives

The primary endpoint of this sub-study was the change in CRP between 24 months and baseline. The relationship between CRP and MS score was a secondary endpoint.

Follow-up

Patients returned to the study site after 12 hours fast at 3, 6, 12, 18 and 24 months when blinded lipid and safety measurements (creatinin kinase, ALT) were performed. CRP was measured at baseline and at 24 months.

Laboratory investigations

Lipid and safety measurements were performed at the Department of Clinical Chemistry and Hematology of the HAGA Hospital, according to ISO 15189 standard procedures. Blood samples were collected from the subjects after a 12 hour fast. EDTA tubes were used for the determination of HbA1c. Liver enzymes and lipids were measured in serum. A urine sample was collected for the determination of the albumin-to-creatinin ratio.

The high sensitive CRP assay was performed in the Leiden University Medical Center with the Tina Quant C-reactive protein (latex) high sensitive assay from Roche using particle enhanced immunoturbidimetry on a Roche Module P(Basel, Switzerland). The lower detection limit (analytical sensitivity) is 0.03 mg/L and the functional sensitivity 0.11 mg/L. The intra-assay CV is 1.34% at 0.55 mg/L and the inter-assay CV is 5.70% at 0.52 mg/L. All CRP assays were performed after completion of the study.

Statistical analysis

The primary treatment comparison was between placebo and statin therapy in patients completing the study, as on-treatment analysis. CRP values more than 15 mg/L were excluded. As CRP values were not normally distributed, logarithmic transformations were used. Changes within each treatment group were analyzed using Student's paired t-test. Comparisons of the effects between the treatment groups were performed using Student's independent samples t-test. Analysis of the baseline data was performed in all randomized patients. Step-wise regression techniques were used to investigate the effect of baseline characteristics on baseline CRP and on changes in CRP. ANOVA was used to investigate the relation between the MS score (1 point for every criterion (waist, triglycerides, HDL cholesterol and blood pressure) according to the NCEP/ATPIII criteria²⁵) and baseline CRP. In addition, the effect of statin treatment on CRP was analyzed in a high-risk patient group with 3 or 4 additional MS criteria on top of their diabetes and LDL cholesterol levels > 2.6 mmol/L²⁶. To test the equivalence of cerivastatin 0.4 mg and simvastatin 20 mg, LDL levels before and after the switch to simvastatin were compared using Student's paired t-test. Correlation between changes in CRP and changes in other parameters were evaluated with Pearson's correlation coefficients.

Analyses were performed using SPSS 11.0 for Windows software. All analyses were 2-sided, with a level of significance of $\alpha = 0.05$.

RESULTS

The characteristics of the study population are given in Table 1. No statistical differences between the groups were observed. 68 patients did not complete the study. This relatively high drop-out rate was mainly caused by the withdrawal of cerivastatin from the market²⁴. There were no significant differences in demographic or lipid parameters between the full cohort (n=250) and the patients completing the study (n=182), except for race as more Caucasians than non-Caucasians completed the study (data not shown).

Table 1 Baseline Characteristics of 250 Randomized Patients

	Placebo (n=125)	Statin (n=125)
Male sex	57 (46)	61 (49)
Age (years)	58.2 $\pm$ 11.4	58.8 $\pm$ 11.3
Ethnicity:		
Caucasian	86 (69)	83 (66)
Asian-Indians	20 (16)	28 (22)
other	19 (15)	14 (11)
Current smoker	33 (26)	28 (22)
Hypertension	66 (53)	60 (48)
Diabetes duration (years)*	7 $\pm$ 8	6 $\pm$ 7
Insulin use	69 (55)	62 (50)

Data are means $\pm$ SD or numbers of patients (%). *Median $\pm$ SD.

CRP measurements (Table 2)

Baseline CRP was not significantly different between the groups. Baseline CRP in the drop-outs did not differ from values in patients completing the study. A total of 149 patients had analyzable CRP data (i.e. < 15 mg/L) at baseline and 24 months.

There was no significant difference between the change in CRP in 2 years in the statin group and the placebo group (mean difference 0.53 mg/L [95% CI -0.42 to 1.48 mg/L] $p=0.269$). CRP in the placebo group increased from 2.03 mg/L at baseline to 2.54 mg/L at 2 years ($p = 0.058$), in the statin group it was 1.58 mg/L at baseline and 1.69 mg/L at 2 years ($p=0.413$).

Determinants for baseline CRP in univariate analysis were waist, Body Mass Index (BMI), HbA1c, age, gender (higher in women), ethnicity (higher in caucasians and Asian-Indians), smoking, triglycerides, apoB/LDL cholesterol, diabetes medication and MS score. When included into a regression model, age ($\beta = -0.005$, $p = 0.031$), BMI ($\beta = 0.019$, $p < 0.001$), HbA1c ($\beta = 0.049$, $p = 0.016$), gender ($\beta = 0.171$, $p = 0.003$), ethnicity ($\beta = -0.196$,

Table 2 CRP and metabolic changes

	Parameter	Baseline	24 months	p 0-24 months
Placebo n=64	CRP(mg/L)	2.03	2.54	0.058
	ALT (IU/L)	33	35	0.783
	HbA1c (%)	7.62	7.57	0.764
	BP _{syst} (mmHg)	137	134	0.071
	BP _{diast} (mmHg)	77	74	<0.001
	BMI (kg/m ²)	30.2	30.3	0.696
	Waist(m)	1.03	1.02	0.176
	MS score	2.48	2.22	0.031
	Microalbuminuria (g/mol creat)	3.13	9.74	0.019
Statin n=85	CRP(mg/L)	1.58	1.69	0.413
	ALT (IU/L)	25	26	0.410
	HbA1c (%)	7.49	7.63	0.235
	BP _{syst} (mmHg)	137	132	0.007
	BP _{diast} (mmHg)	77	74	<0.001
	BMI (kg/m ²)	30.1	30.4	0.145
	Waist (m)	1.02	1.01	0.369
	MS score	2.18	2.04	0.141
	Microalbuminuria (g/mol creat)	2.48	5.81	0.053


Data are geometric means for CRP and means for other parameters

p=0.011) and MS score (beta = 0.071, p=0.010) remained significant determinants and together explained 29% of the variance in baseline CRP. The relation between MS score and CRP was linear at baseline (ANOVA p for linearity <0.001) (Figure 1). After 2 years, this relation remained statistically significant only in the placebo group. Further analysis on this issue revealed that in a high-risk subgroup with 3 or more additional MS criteria (on top of their diabetes) and LDL levels > 2.6 mmol/L, which comprised 40% of the cohort (29 patients in the placebo group and 30 patients in the statin group), two years' CRP levels increased significantly in the placebo group (from 2.97 at baseline to 3.99 at 2 years, p=0.036) in comparison to the statin group (from 2.13 mg/L at baseline to 2.10 mg/L at 2 years, p=0.885) (Figure 2, p=0.042 for comparison between placebo and statin)

Changes in CRP were not related to baseline characteristics, changes in lipid levels, body weight or HbA1c. The effect of the two statins used was analyzed by correcting the change in CRP for duration of simvastatin treatment (range 1 to 18 months). This did not change the results.

Lipids


LDL cholesterol was 3.44 ± 0.71 mmol/L at baseline and 2.58 ± 0.95 mmol/L at 2 years (-25 %, p < 0.001) in the statin group and 3.55 ± 0.71 mmol/L at baseline and 3.78 ± 0.81 mmol/L at 2 years (+8 %, p=0.003) in the placebo group (p < 0.001). HDL cholesterol was 1.23 ± 0.39

Figure 1. Relation between MS score and CRP at baseline

mmol/L at baseline and 1.20 ± 0.36 mmol/L at 2 years in the statin group and 1.21 ± 0.37 mmol/L at baseline and 1.22 ± 0.38 mmol/L at 2 years in the placebo group. Triglycerides were 1.82 ± 0.97 mmol/L at baseline and 1.60 ± 1.38 mmol/L at 2 years in the statin group and 1.88 ± 0.79 mmol/L at baseline and 1.72 ± 1.22 mmol/L at 2 years in the placebo group. Changes in HDL cholesterol and triglycerides were not significantly different compared to baseline or compared to the placebo group, except for the reduction in triglycerides in the statin group after 2 years ($p=0.043$). Average LDL cholesterol levels were higher after the switch to simvastatin (2.34 before versus 2.56 mmol/L after the switch, $p < 0.001$).

CONCLUSIONS

Patients with DM2 have a high-risk of cardiovascular events. Many studies have been performed to evaluate new non-traditional risk factors for CVD. The number of studies in DM2

Figure 2. Effect of statin therapy on CRP, stratified by risk group

Changes in CRP (+ SE) after two years, stratified by high-risk (HR) (MS score 3 or 4 and LDL > 2,6 mmol/L) and standard risk (SR) (rest group).

p=0.042 for the difference in changes between placebo and statin in the high-risk group

however is sparse. This is the first randomized controlled trial on the effect of long-term statin therapy on CRP in DM2. We did not find an effect of 2 years' intermediate-dose statin therapy on CRP. Consistent with our results, Koh et al did not find an effect of 2 months of simvastatin 20 mg on CRP in a randomized, placebo-controlled crossover trial in DM2²². In patients with DM2 and low HDL levels, both 40 and 80 mg simvastatin significantly reduced CRP levels¹⁹. Other randomized placebo-controlled studies in DM2 show a dose dependent effect of atorvastatin on CRP^{18,20}. Similarly, pravastatin 40 mg decreased CRP levels in an open, randomized, crossover study in DM2²¹. Balletshofer et al²³ found no effect of 12 weeks cerivastatin 0.2 mg and 0.8 mg on CRP in DM2; this study however included only 20 patients per group because the study was terminated after the withdrawal of cerivastatin.

Possible explanations for the inconsistent findings on the effect of statin therapy on CRP in DM2 are differences in patient inclusion criteria, differential effects of statins, dose-depending effects and duration of statin treatment.

In line with another study⁹, CRP in our asymptomatic DM2 group was related to the MS and to other aspects of glucose metabolism. Interestingly, BMI and MS score were both independently associated with CRP. This is in concordance with the findings of Putz²⁷ and Mc Laughlin²⁸, implicating that the relationship between insulin resistance and CRP is only partly explained by obesity.

Data from NHANES III show that among people with DM2 and MS the prevalence of CVD was higher than among people with DM2 without MS²⁹. We were able to identify a high-risk phenotype, present in 40 % of our cohort, with 3 or 4 additional MS criteria on top of their

diabetes and LDL levels > 2.6 mmol/L. These patients showed a significant effect of statin therapy on CRP in comparison to placebo. Intriguingly, this effect occurred only when the combination of MS and higher LDL levels was present. This important observation suggests that statins are most effective at reducing low grade inflammation in high-risk groups and supports risk stratification in the prescription of statin therapy in primary prevention in DM2. As advocated by the NCEP²⁶, statin therapy should be prescribed to DM2 individuals without CVD with LDL levels > 2.6 mmol/L and at least one additional cardiovascular risk factor.

We explored the effect of diabetes related factors as a possible cause of the (non-significant) rise in CRP in the placebo group. We found no changes in HbA1c after 24 months; blood pressure was significantly lower after 24 months although there was progression of microalbuminuria; One has to realize however, that in our regression model only 29% of the variance in CRP could be explained and that the diabetic state itself and genetic factors³⁰ might be major determinants of CRP.

Our study has limitations: the switch from cerivastatin to simvastatin was unplanned and we did not have the possibility to collect blood samples at the time of the switch. All our 24 month samples were collected after the switch, after 1-18 months of simvastatin treatment. In addition, we did not find an influence of the duration of simvastatin treatment on the 24 months results in regression analysis. The statin dose used was relatively low, but common in primary prevention during the time this study was started.

In conclusion, the present study showed no effect of two year statin therapy on CRP in patients with DM2 without manifest CVD. The beneficial effects of statin therapy on CRP in a high-risk subgroup with MS and LDL > 2.6 mmol/L supports the use of risk stratification in DM2. Prospective studies are needed to further substantiate these findings.

REFERENCES

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care* 16:434-444, 1993
2. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, Dhillon B, Mickle DA: Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. *Circulation* 105:1890-1896, 2002
3. Pasceri V, Willerson JT, Yeh ET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. *Circulation* 102:2165-2168, 2000
4. Yeh ET: A new perspective on the biology of C-reactive protein. *Circ.Res.* 97:609-611, 2005
5. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. *N.Engl.J.Med.* 347:1557-1565, 2002
6. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N.Engl.J.Med.* 342:836-843, 2000
7. Ridker PM, Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. *Circulation* 107:391-397, 2003
8. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW: C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? *Arterioscler.Thromb.Vasc.Biol.* 19:972-978, 1999
9. Kang ES, Kim HJ, Ahn CW, Park CW, Cha BS, Lim SK, Kim KR, Lee HC: Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes. *Diabetes Res.Clin.Pract.* 69:151-159, 2005
10. Snijder MB, Dekker JM, Visser M, Bouter LM, Stehouwer CD, Kostense PJ, Yudkin JS, Heine RJ, Nijpels G, Seidell JC: Associations of hip and thigh circumferences independent of waist circumference with the incidence of type 2 diabetes: the Hoorn Study. *Am.J.Clin.Nutr.* 77:1192-1197, 2003
11. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM: Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. *Diabetes Care* 25:2016-2021, 2002
12. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, O'Reilly DS, Packard CJ, Sattar N: C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. *Diabetes* 51:1596-1600, 2002
13. Wannamethee SG, Lowe GD, Shaper AG, Rumley A, Lennon L, Whincup PH: Insulin resistance, haemostatic and inflammatory markers and coronary heart disease risk factors in Type 2 diabetic men with and without coronary heart disease. *Diabetologia* 47:1557-1565, 2004
14. Schulze MB, Rimm EB, Li T, Rifai N, Stampfer MJ, Hu FB: C-reactive protein and incident cardiovascular events among men with diabetes. *Diabetes Care* 27:889-894, 2004
15. Matsumoto K, Sera Y, Abe Y, Ueki Y, Tominaga T, Miyake S: Inflammation and insulin resistance are independently related to all-cause of death and cardiovascular events in Japanese patients with type 2 diabetes mellitus. *Atherosclerosis* 169:317-321, 2003
16. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD: von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and non-diabetic subjects: the Hoorn Study. *Arterioscler.Thromb.Vasc.Biol.* 19:3071-3078, 1999
17. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E: C-reactive protein levels and outcomes after statin therapy. *N.Engl.J.Med.* 352:20-28, 2005

18. van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C: Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. *Atherosclerosis* 166:129-135, 2003
19. Miller M, Dobs A, Yuan Z, Battisti WP, Borisute H, Palmisano J: Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C. *Curr.Med.Res.Opin.* 20:1087-1094, 2004
20. Tan KC, Chow WS, Tam SC, Ai VH, Lam CH, Lam KS: Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. *J.Clin.Endocrinol. Metab* 87:563-568, 2002
21. Sommeijer DW, MacGillavry MR, Meijers JC, Van Zanten AP, Reitsma PH, Ten Cate H: Anti-inflammatory and anticoagulant effects of pravastatin in patients with type 2 diabetes. *Diabetes Care* 27:468-473, 2004
22. Koh KK, Quon MJ, Han SH, Ahn JY, Jin DK, Kim HS, Kim DS, Shin EK: Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. *Hypertension* 45:1088-1093, 2005
23. Balletshofer BM, Goebbel S, Rittig K, Enderle M, Schmolzer I, Wascher TC, Ferenc PA, Westermeier T, Petzinna D, Matthaei S, Haring HU: Intense cholesterol lowering therapy with a HMG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type-2-diabetes--a multicenter, randomized, double-blind, three-arm placebo-controlled clinical trial. *Exp.Clin.Endocrinol.Diabetes* 113:324-330, 2005
24. Beishuizen ED, van de Ree MA, Jukema JW, Tamsma JT, van der Vijver JC, Meinders AE, Putter H, Huisman MV: Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease. *Diabetes Care* 27:2887-2892, 2004
25. Grundy SM, Brewer HB, Jr., Cleeman JI, Smith SC, Jr., Lenfant C: Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. *Circulation* 109:433-438, 2004
26. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr., Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Jr., Stone NJ: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation* 110:227-239, 2004
27. Putz DM, Goldner WS, Bar RS, Haynes WG, Sivitz WI: Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy. *Metabolism* 53:1454-1461, 2004
28. McLaughlin T, Abbasi F, Lamendola C, Liang L, Reaven G, Schaaf P, Reaven P: Differentiation between obesity and insulin resistance in the association with C-reactive protein. *Circulation* 106:2908-2912, 2002
29. Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. *Diabetes* 52:1210-1214, 2003
30. Timpson NJ, Lawlor DA, Harbord RM, Gaunt TR, Day IN, Palmer LJ, Hattersley AT, Ebrahim S, Lowe GD, Rumley A, Davey SG: C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. *Lancet* 366:1954-1959, 2005

